Alembic Pharmaceuticals, 533573, APLLTD Share Price, Rating, Research, Analysis, Fundamental & Historical Data

Stock Summary

Market Cap(Crs)
Stock P:E
Face Value

19,246.48
31.91
2

Enterprise Value(Crs)
Dividend Yield
Price:Book Value

20,351.96
1.12%
3.60

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

10 Years
5 Years
3 Years

7.74
4.35
5.68

EBITDA CAGR (%)

10 Years
5 Years
3 Years

-0.02
-7.49
7.21

PAT CAGR (%)

10 Years
5 Years
3 Years

-2.08
-12.15
19.49

P:E (Median)

8 Years
5 Years
3 Years

25.09
28.80
33.18

P:BV (Average)

8 Years
5 Years
3 Years

3.73
3.39
3.38

EV:EBITDA (Average)

8 Years
5 Years
3 Years

15.86
16.88
19.05

Earnings Forecasts:

(Updated: 06-06-2025)

Description 2024 2025 2026 2027
Adj EPS 31.33 29.68 36.67 47.2
P/E Ratio 31.22 32.95 26.67 20.72
Revenue 6229 6672 7406 8213
EBITDA 933 1008 1232 1498
Net Income 616 583 721 928
ROA 9.8 8.2 11.1 13.3
P/B Ratio 3.92 3.70 3.37 3.01
ROE 13.4 11.66 13.19 15.27
FCFF 430 -548 595 589
FCFF Yield 2.09 -2.66 2.89 2.86
Net Debt 387 1167 491 67
BVPS 249.74 264.1 289.96 324.74

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone

Description Jun 25 Jun 24 Var% Mar 25 Mar 24 Var% Dec 24 Dec 23 Var% Sep 24 Sep 23 Var%
Net Sales 1,494.17 1,475.56 1.26% 1,570.64 1,474.55 6.52% 1,406.09 1,588.39 -11.48% 1,580.35 1,478.84 6.86%
Expenses 1,280.43 1,184.13 8.13% 1,399.98 1,186.36 18.01% 1,226.26 1,251.25 -2.00% 1,320.86 1,271.38 3.89%
EBITDA 213.74 291.43 -26.66% 170.66 288.19 -40.78% 179.83 337.14 -46.66% 259.49 207.46 25.08%
EBIDTM 14.30% 19.75% 10.87% 19.54% 12.79% 21.23% 16.42% 14.03%
Other Income 7.79 3.14 148.09% 13.21 7.22 82.96% 15.46 3.30 368.48% 16.06 8.95 79.44%
Interest 22.64 12.69 78.41% 23.71 10.13 134.06% 21.79 14.66 48.64% 18.28 15.39 18.78%
Depreciation 73.37 68.68 6.83% 68.60 69.12 -0.75% 69.69 69.08 0.88% 70.12 67.18 4.38%
PBT 125.52 213.20 -41.13% 91.56 216.16 -57.64% 103.81 256.70 -59.56% 200.02 133.84 49.45%
Tax 22.00 37.01 -40.56% 16.22 14.29 13.51% 18.00 23.46 -23.27% 34.24 0.00 0
PAT 103.52 176.19 -41.25% 75.34 201.87 -62.68% 85.81 233.24 -63.21% 165.78 133.84 23.86%
PATM 6.93% 11.94% 4.80% 13.69% 6.10% 14.68% 10.49% 9.05%
EPS 5.27 8.96 -41.18% 3.83 10.27 -62.71% 4.36 11.86 -63.24% 8.43 6.81 23.79%

Description Jun 25 Jun 24 Var% Mar 25 Mar 24 Var% Dec 24 Dec 23 Var% Sep 24 Sep 23 Var%
Net Sales 1,710.72 1,561.73 9.54% 1,769.64 1,516.97 16.66% 1,692.75 1,630.57 3.81% 1,647.98 1,594.93 3.33%
Expenses 1,429.38 1,324.90 7.89% 1,497.71 1,256.92 19.16% 1,432.52 1,364.21 5.01% 1,408.71 1,386.69 1.59%
EBITDA 281.34 236.83 18.79% 271.93 260.05 4.57% 260.23 266.36 -2.30% 239.27 208.24 14.90%
EBIDTM 16.45% 15.16% 15.37% 17.14% 15.37% 16.34% 14.52% 13.06%
Other Income 6.50 2.10 209.52% 14.19 3.60 294.17% 9.50 2.89 228.72% 16.74 10.15 64.93%
Interest 23.52 13.18 78.45% 24.52 10.94 124.13% 22.26 15.17 46.74% 18.81 15.69 19.89%
Depreciation 73.77 69.04 6.85% 68.99 69.48 -0.71% 70.04 69.45 0.85% 70.51 67.56 4.37%
PBT 190.55 156.71 21.59% 192.61 183.23 5.12% 177.43 184.63 -3.90% 179.56 135.14 32.87%
Tax 36.47 22.49 62.16% 35.32 4.63 662.85% 40.09 4.13 870.70% 27.28 -1.93 -
PAT 154.08 134.22 14.80% 157.29 178.60 -11.93% 137.34 180.50 -23.91% 152.28 137.07 11.10%
PATM 9.01% 8.59% 8.89% 11.77% 8.11% 11.07% 9.24% 8.59%
EPS 7.85 6.85 14.60% 7.98 9.07 -12.02% 7.04 9.18 -23.31% 7.81 6.95 12.37%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone

Description TTM Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Net Sales 6,051.25 6,032.63 5,874.06 5,149.00 5,035.40 5,066.88 4,132.56 3,660.28 2,945.26 2,985.90 3,009.02 Net Sales Growth 0.56% 2.70% 14.08% 2.26% -0.62% 22.61% 12.90% 24.28% -1.36% -0.77% Cost Of Goods Sold 1,817.43 1,788.77 1,800.35 1,660.13 1,502.21 1,304.03 1,045.87 1,000.08 893.36 915.74 854.53 Gross Profit 4,233.82 4,243.86 4,073.71 3,488.87 3,533.19 3,762.85 3,086.69 2,660.20 2,051.90 2,070.16 2,154.49 GP Margin 69.97% 70.35% 69.35% 67.76% 70.17% 74.26% 74.69% 72.68% 69.67% 69.33% 71.60% Total Expenditure 5,227.53 5,136.55 4,876.27 4,484.97 4,126.63 3,617.71 2,940.87 2,800.98 2,346.65 2,353.36 2,061.47 Power & Fuel Cost - 179.67 173.32 151.19 120.50 118.31 97.43 88.44 70.21 64.13 58.84 % Of Sales - 2.98% 2.95% 2.94% 2.39% 2.33% 2.36% 2.42% 2.38% 2.15% 1.96% Employee Cost - 1,466.57 1,335.91 1,094.82 1,062.30 976.13 806.37 684.45 582.72 527.46 453.32 % Of Sales - 24.31% 22.74% 21.26% 21.10% 19.26% 19.51% 18.70% 19.79% 17.67% 15.07% Manufacturing Exp. - 397.72 348.85 386.28 374.69 369.82 323.09 254.55 226.57 241.01 184.80 % Of Sales - 6.59% 5.94% 7.50% 7.44% 7.30% 7.82% 6.95% 7.69% 8.07% 6.14% General & Admin Exp. - 535.52 497.23 464.08 390.16 377.29 311.21 319.33 269.55 283.40 219.09 % Of Sales - 8.88% 8.46% 9.01% 7.75% 7.45% 7.53% 8.72% 9.15% 9.49% 7.28% Selling & Distn. Exp. - 724.78 673.69 679.85 647.93 445.87 318.14 422.79 273.56 298.84 266.86 % Of Sales - 12.01% 11.47% 13.20% 12.87% 8.80% 7.70% 11.55% 9.29% 10.01% 8.87% Miscellaneous Exp. - 43.52 46.92 48.62 28.84 26.26 38.76 31.34 30.68 22.78 266.86 % Of Sales - 0.72% 0.80% 0.94% 0.57% 0.52% 0.94% 0.86% 1.04% 0.76% 0.80% EBITDA 823.72 896.08 997.79 664.03 908.77 1,449.17 1,191.69 859.30 598.61 632.54 947.55 EBITDA Margin 13.61% 14.85% 16.99% 12.90% 18.05% 28.60% 28.84% 23.48% 20.32% 21.18% 31.49% Other Income 52.52 53.19 32.05 3.85 51.17 84.08 145.96 25.79 40.59 3.28 42.00 Interest 86.42 76.47 54.47 49.00 17.02 12.98 25.19 14.87 2.22 3.21 3.68 Depreciation 281.78 277.08 271.14 272.95 284.92 182.53 135.67 105.59 101.76 82.90 71.86 PBT 520.91 595.72 704.23 345.93 658.00 1,337.74 1,176.79 764.63 535.22 549.71 914.01 Tax 90.46 105.47 37.75 -0.80 114.45 241.20 197.39 153.42 113.23 119.08 215.27 Tax Rate 17.37% 17.33% 5.36% -0.23% 17.39% 18.03% 16.92% 20.06% 21.16% 21.66% 23.55% PAT 430.45 503.12 666.48 346.73 543.55 1,096.54 969.40 611.21 421.99 430.63 698.74 PAT before Minority Interest 430.45 503.12 666.48 346.73 543.55 1,096.54 969.40 611.21 421.99 430.63 698.74 Minority Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT Margin 7.11% 8.34% 11.35% 6.73% 10.79% 21.64% 23.46% 16.70% 14.33% 14.42% 23.22% PAT Growth -42.23% -24.51% 92.22% -36.21% -50.43% 13.12% 58.60% 44.84% -2.01% -38.37% EPS 21.89 25.59 33.90 17.64 27.65 55.78 49.31 31.09 21.46 21.90 35.54

Description TTM Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Net Sales 6,821.09 6,672.08 6,228.63 5,652.62 5,305.78 5,393.14 4,605.76 3,934.69 3,130.81 3,134.61 3,165.99 Net Sales Growth 8.20% 7.12% 10.19% 6.54% -1.62% 17.10% 17.06% 25.68% -0.12% -0.99% Cost Of Goods Sold 1,806.68 1,793.36 1,715.08 1,708.82 1,446.43 1,257.35 1,039.38 992.71 886.19 887.57 823.95 Gross Profit 5,014.41 4,878.72 4,513.55 3,943.80 3,859.35 4,135.79 3,566.38 2,941.98 2,244.62 2,247.04 2,342.04 GP Margin 73.51% 73.12% 72.46% 69.77% 72.74% 76.69% 77.43% 74.77% 71.69% 71.68% 73.97% Total Expenditure 5,768.32 5,669.16 5,296.00 4,944.56 4,431.64 3,913.05 3,391.69 3,078.87 2,515.55 2,519.90 2,160.88 Power & Fuel Cost - 179.69 173.37 151.54 120.84 118.72 102.40 88.86 70.35 64.20 58.89 % Of Sales - 2.69% 2.78% 2.68% 2.28% 2.20% 2.22% 2.26% 2.25% 2.05% 1.86% Employee Cost - 1,562.34 1,446.29 1,169.13 1,133.00 1,051.17 906.44 746.69 622.81 558.83 472.85 % Of Sales - 23.42% 23.22% 20.68% 21.35% 19.49% 19.68% 18.98% 19.89% 17.83% 14.94% Manufacturing Exp. - 440.63 387.71 409.37 379.15 372.18 368.41 269.25 244.53 289.79 271.51 % Of Sales - 6.60% 6.22% 7.24% 7.15% 6.90% 8.00% 6.84% 7.81% 9.24% 8.58% General & Admin Exp. - 576.40 525.84 492.64 413.90 391.24 339.82 340.56 283.43 299.79 233.28 % Of Sales - 8.64% 8.44% 8.72% 7.80% 7.25% 7.38% 8.66% 9.05% 9.56% 7.37% Selling & Distn. Exp. - 1,064.86 996.88 952.30 890.38 687.41 531.19 590.28 380.21 393.14 274.14 % Of Sales - 15.96% 16.00% 16.85% 16.78% 12.75% 11.53% 15.00% 12.14% 12.54% 8.66% Miscellaneous Exp. - 51.88 50.83 60.76 47.94 34.98 104.05 50.52 28.03 26.58 274.14 % Of Sales - 0.78% 0.82% 1.07% 0.90% 0.65% 2.26% 1.28% 0.90% 0.85% 0.83% EBITDA 1,052.77 1,002.92 932.63 708.06 874.14 1,480.09 1,214.07 855.82 615.26 614.71 1,005.11 EBITDA Margin 15.43% 15.03% 14.97% 12.53% 16.48% 27.44% 26.36% 21.75% 19.65% 19.61% 31.75% Other Income 46.93 47.86 29.04 3.04 50.49 87.48 13.88 27.14 34.87 2.58 8.83 Interest 89.11 78.77 56.19 50.17 17.73 16.02 27.16 18.41 3.40 5.23 5.43 Depreciation 283.31 278.57 272.67 275.43 286.78 183.47 157.32 115.23 105.46 82.97 72.21 PBT 740.15 693.44 632.81 385.50 620.12 1,368.08 1,043.47 749.32 541.27 529.09 936.30 Tax 139.16 125.17 16.01 12.60 104.46 253.32 199.18 156.75 120.36 122.19 216.12 Tax Rate 18.80% 17.72% 2.53% 3.27% 16.85% 18.52% 19.92% 20.92% 22.24% 23.09% 23.08% PAT 600.99 583.42 615.82 341.99 520.94 1,114.76 828.76 593.65 420.72 406.99 720.18 PAT before Minority Interest 602.99 582.01 615.82 341.99 520.94 1,114.76 800.64 592.57 420.91 406.90 720.18 Minority Interest 2.00 1.41 0.00 0.00 0.00 0.00 28.12 1.08 -0.19 0.09 0.00 PAT Margin 8.81% 8.74% 9.89% 6.05% 9.82% 20.67% 17.99% 15.09% 13.44% 12.98% 22.75% PAT Growth -4.66% -5.26% 80.07% -34.35% -53.27% 34.51% 39.60% 41.10% 3.37% -43.49% EPS 30.57 29.68 31.32 17.40 26.50 56.70 42.15 30.20 21.40 20.70 36.63

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Shareholder's Funds 5,194.74 4,908.91 4,414.29 5,290.34 5,101.81 3,346.02 2,712.41 2,194.63 1,867.32 1,530.73 Share Capital 39.31 39.31 39.31 39.31 39.31 37.70 37.70 37.70 37.70 37.70 Total Reserves 5,155.43 4,869.60 4,374.98 5,251.03 5,062.50 3,308.32 2,674.71 2,156.93 1,829.62 1,493.03 Non-Current Liabilities 84.51 83.59 86.67 204.25 403.08 1,079.25 595.88 585.07 101.00 83.91 Secured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Unsecured Loans 0.00 0.00 0.00 0.00 199.89 886.99 499.30 500.00 0.00 0.00 Long Term Provisions 124.31 109.51 106.20 95.82 85.52 73.21 51.32 40.43 57.22 28.23 Current Liabilities 2,285.86 1,368.40 1,551.30 1,694.45 1,378.36 1,453.49 1,397.76 1,011.69 658.79 763.15 Trade Payables 724.57 619.96 595.86 570.21 527.00 393.17 472.75 601.98 430.11 499.76 Other Current Liabilities 230.05 222.34 250.41 515.60 557.86 222.12 375.65 140.28 80.35 51.32 Short Term Borrowings 1,142.22 420.04 635.07 430.00 0.02 800.04 359.98 121.53 8.28 0.00 Short Term Provisions 189.02 106.06 69.96 178.64 293.48 38.16 189.38 147.90 140.05 212.07 Total Liabilities 7,565.11 6,360.90 6,052.26 7,189.04 6,883.25 5,878.76 4,706.05 3,791.39 2,627.11 2,377.79 Net Block 2,513.47 2,535.66 2,377.47 1,771.10 1,773.82 1,276.46 1,085.44 918.30 799.01 697.25 Gross Block 4,100.64 3,859.15 3,441.30 2,733.11 2,452.31 1,761.68 1,435.06 1,162.61 948.64 1,082.45 Accumulated Depreciation 1,587.17 1,323.49 1,063.83 962.01 678.49 485.22 349.62 244.31 149.63 385.20 Non Current Assets 3,712.65 3,331.16 3,272.05 4,329.58 4,148.87 3,727.40 2,713.03 2,002.20 1,286.33 857.01 Capital Work in Progress 837.23 524.36 601.28 2,304.24 2,182.53 1,569.98 1,106.89 740.64 347.75 92.34 Non Current Investment 259.56 226.68 229.27 219.36 156.12 833.25 506.39 298.89 103.04 37.46 Long Term Loans & Adv. 102.39 44.46 64.03 34.88 36.40 47.71 14.31 44.37 36.53 29.96 Other Non Current Assets 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Current Assets 3,852.46 3,029.74 2,780.21 2,859.46 2,734.38 2,151.36 1,993.02 1,789.19 1,340.78 1,520.78 Current Investments 0.00 0.00 0.00 0.00 186.97 0.00 0.00 0.00 0.00 0.00 Inventories 1,976.34 1,353.07 1,275.13 1,396.83 1,341.95 1,073.18 891.42 669.93 574.62 533.72 Sundry Debtors 1,480.67 1,340.12 1,201.20 988.33 421.86 784.11 539.78 621.66 467.41 371.50 Cash & Bank 20.84 26.49 28.46 21.90 61.44 37.13 150.80 15.63 7.21 284.81 Other Current Assets 374.61 53.26 48.19 44.71 722.16 256.94 411.02 481.97 291.54 330.75 Short Term Loans & Adv. 312.91 256.80 227.23 407.69 650.61 234.58 397.95 458.60 285.95 324.85 Net Current Assets 1,566.60 1,661.34 1,228.91 1,165.01 1,356.02 697.87 595.26 777.50 681.99 757.63 Total Assets 7,565.11 6,360.90 6,052.26 7,189.04 6,883.25 5,878.76 4,706.05 3,791.39 2,627.11 2,377.79

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Shareholder's Funds 5,190.94 4,818.20 4,370.47 5,237.54 5,066.98 3,219.42 2,718.83 2,220.14 1,902.33 1,597.36 Share Capital 39.31 39.31 39.31 39.31 39.31 37.70 37.70 37.70 37.70 37.70 Total Reserves 5,151.63 4,778.89 4,331.16 5,198.23 5,027.67 3,181.72 2,681.13 2,182.44 1,864.63 1,559.66 Non-Current Liabilities 5.05 2.75 52.42 162.07 361.16 1,046.98 570.06 576.20 94.15 84.02 Secured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Unsecured Loans 0.00 0.00 0.00 0.00 199.89 886.99 499.30 500.00 0.00 0.00 Long Term Provisions 124.31 109.51 106.20 95.82 85.52 74.51 52.03 40.76 57.22 28.23 Current Liabilities 2,514.27 1,520.28 1,640.80 1,830.59 1,533.26 1,751.61 1,663.65 1,267.18 813.96 944.19 Trade Payables 879.89 735.64 679.81 706.39 668.78 625.93 644.34 759.32 500.73 565.65 Other Current Liabilities 232.10 223.66 251.19 516.51 557.92 226.98 380.19 142.89 81.28 51.80 Short Term Borrowings 1,195.57 430.45 635.87 430.00 0.02 860.50 429.13 207.78 88.51 113.71 Short Term Provisions 206.71 130.53 73.93 177.69 306.54 38.20 209.99 157.19 143.44 213.03 Total Liabilities 7,708.84 6,341.23 6,063.69 7,230.20 6,961.40 5,989.05 4,951.75 4,063.83 2,810.55 2,625.57 Net Block 2,523.53 2,546.71 2,398.45 1,797.85 1,788.42 1,551.84 1,158.45 993.38 799.40 708.09 Gross Block 4,117.32 3,875.21 3,467.50 2,840.33 2,545.39 2,132.41 1,522.57 1,242.47 950.09 1,093.63 Accumulated Depreciation 1,593.79 1,328.50 1,069.05 1,042.48 756.97 580.57 364.12 249.09 150.69 385.54 Non Current Assets 3,519.12 3,197.39 3,149.80 4,255.37 4,056.96 3,526.30 2,820.02 2,116.31 1,316.80 917.30 Capital Work in Progress 837.23 524.36 601.28 2,304.24 2,182.53 1,846.18 1,551.23 1,010.15 396.28 92.52 Non Current Investment 127.21 93.02 96.33 118.40 49.31 17.62 48.76 41.64 49.88 53.43 Long Term Loans & Adv. 31.15 33.30 53.74 34.88 36.70 110.66 61.58 71.14 71.24 29.96 Other Non Current Assets 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 33.30 Current Assets 4,189.72 3,143.84 2,913.89 2,974.83 2,904.44 2,462.75 2,131.73 1,947.52 1,493.75 1,708.27 Current Investments 0.00 0.00 0.00 0.00 186.97 0.00 0.00 0.00 0.00 0.00 Inventories 2,288.14 1,643.54 1,475.27 1,609.70 1,486.15 1,187.54 967.27 733.93 632.75 569.79 Sundry Debtors 1,399.79 1,024.84 1,046.41 807.13 348.60 864.75 488.92 526.34 338.82 350.48 Cash & Bank 90.09 126.57 82.27 69.43 105.84 80.75 205.62 89.92 159.60 450.83 Other Current Assets 411.70 59.86 55.32 51.65 776.88 329.71 469.92 597.33 362.58 337.17 Short Term Loans & Adv. 342.52 289.03 254.62 436.92 698.21 301.61 451.71 569.84 355.02 330.08 Net Current Assets 1,675.45 1,623.56 1,273.09 1,144.24 1,371.18 711.14 468.08 680.34 679.79 764.08 Total Assets 7,708.84 6,341.23 6,063.69 7,230.20 6,961.40 5,989.05 4,951.75 4,063.83 2,810.55 2,625.57

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Cash From Operating Activity 226.57 772.77 730.25 545.26 1,388.48 539.75 808.80 304.55 327.16 847.52 PBT 608.59 704.23 345.93 658.01 1,337.74 1,166.79 764.63 535.22 549.71 914.01 Adjustment 365.07 284.21 448.49 413.35 92.60 30.14 91.48 81.90 84.88 72.96 Changes in Working Capital -701.42 -205.64 -10.39 -397.30 198.56 -460.39 110.38 -188.46 -189.44 56.63 Cash after chg. in Working capital 272.24 782.80 784.03 674.06 1,628.90 736.54 966.49 428.66 445.15 1,043.60 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -45.67 -10.03 -53.78 -128.80 -240.42 -196.79 -157.69 -124.11 -117.99 -196.08 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity -636.08 -329.02 -460.98 -368.72 -835.72 -822.32 -753.60 -793.58 -510.97 -291.91 Net Fixed Assets -554.36 -340.93 994.77 -402.51 -1,303.18 -789.71 -638.70 -606.86 -121.60 -288.80 Net Investments -32.88 2.59 -9.91 123.73 490.16 -326.86 -207.50 -195.85 -65.58 -4.13 Others -48.84 9.32 -1,445.84 -89.94 -22.70 294.25 92.60 9.13 -323.79 1.02 Cash from Financing Activity 403.61 -445.29 -261.16 -216.64 -533.75 166.13 79.67 497.80 -96.06 -276.05 Net Cash Inflow / Outflow -5.90 -1.54 8.11 -40.10 19.01 -116.44 134.87 8.77 -279.87 279.56 Opening Cash & Equivalents 20.13 21.67 13.56 53.66 35.58 144.25 9.45 0.68 280.56 0.99 Closing Cash & Equivalent 14.23 20.13 21.67 13.56 53.66 28.22 144.25 9.45 0.69 280.55

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Cash From Operating Activity 87.96 803.20 723.94 552.35 1,463.38 449.15 811.97 312.42 328.55 947.65 PBT 707.18 631.83 354.59 625.39 1,368.08 999.82 749.32 541.27 529.09 936.31 Adjustment 373.53 286.87 487.61 417.75 102.42 278.28 117.57 87.12 83.06 69.45 Changes in Working Capital -921.36 -95.65 -57.56 -367.36 238.30 -592.84 111.56 -180.85 -165.64 138.90 Cash after chg. in Working capital 159.35 823.05 784.64 675.78 1,708.80 685.26 978.45 447.54 446.51 1,144.66 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -71.39 -19.85 -60.70 -123.43 -245.42 -236.11 -166.48 -135.12 -117.96 -197.01 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity -568.41 -320.61 -447.59 -371.97 -838.80 -731.63 -755.60 -884.38 -485.91 -306.80 Net Fixed Assets -554.36 -340.93 994.77 -402.51 -1,303.18 -789.71 -638.70 -606.86 -121.60 -288.80 Net Investments -32.88 2.59 -9.91 123.73 490.16 -326.86 -207.50 -195.85 -65.58 -4.13 Others 18.83 17.73 -1,432.45 -93.19 -25.78 384.94 90.60 -81.67 -298.73 -13.87 Cash from Financing Activity 443.72 -437.86 -261.96 -217.35 -597.42 154.85 59.03 502.63 -128.88 -224.30 Net Cash Inflow / Outflow -36.73 44.73 14.39 -36.97 27.16 -127.63 115.40 -69.33 -286.24 416.55 Opening Cash & Equivalents 120.21 75.48 61.09 98.06 71.83 199.06 83.74 153.07 439.32 22.77 Closing Cash & Equivalent 83.48 120.21 75.48 61.09 98.06 71.84 199.07 83.74 153.08 439.32

Financial Ratios

Consolidated /

Standalone

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Book Value (Rs.) 264.30 249.75 224.59 269.16 259.57 177.51 143.89 116.43 99.06 81.21 ROA 7.23% 10.74% 5.24% 7.73% 17.18% 18.32% 14.39% 13.15% 17.21% 35.93% ROE 9.96% 14.30% 7.15% 10.46% 25.96% 32.00% 24.91% 20.78% 25.35% 59.11% ROCE 11.74% 14.62% 7.20% 11.72% 25.40% 27.08% 23.66% 22.91% 32.46% 71.75% Fixed Asset Turnover 1.52 1.61 1.67 1.94 2.41 2.59 2.82 2.79 2.94 3.19 Receivable days 85.33 78.96 77.61 51.11 43.44 58.46 57.91 67.48 51.27 43.03 Inventory Days 100.72 81.66 94.70 99.26 86.99 86.76 77.85 77.12 67.74 55.57 Payable days 137.18 123.25 128.19 133.30 128.78 54.44 74.24 86.97 79.07 76.51 Cash Conversion Cycle 48.88 37.36 44.12 17.08 1.65 90.78 61.52 57.63 39.94 22.09 Total Debt/Equity 0.22 0.09 0.14 0.12 0.10 0.50 0.39 0.28 0.00 0.00 Interest Cover 8.96 13.93 8.06 39.66 104.06 47.32 52.42 242.09 172.25 249.37

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Book Value (Rs.) 264.10 245.14 222.36 266.47 257.80 170.79 144.24 117.78 100.92 84.74 ROA 8.28% 9.93% 5.15% 7.34% 17.22% 14.64% 13.15% 12.25% 14.97% 33.76% ROE 11.63% 13.40% 7.12% 10.11% 26.91% 26.97% 24.00% 20.42% 23.25% 58.03% ROCE 13.51% 13.42% 7.44% 11.25% 26.28% 23.30% 22.66% 22.15% 28.87% 65.87% Fixed Asset Turnover 1.67 1.70 1.79 1.97 2.31 2.52 2.85 2.86 3.07 3.24 Receivable days 66.32 60.69 59.84 39.75 41.06 53.64 47.09 50.43 40.13 41.02 Inventory Days 107.54 91.38 99.60 106.49 90.48 85.38 78.91 79.67 70.01 54.91 Payable days 164.40 150.62 148.04 173.51 187.92 69.87 88.23 98.47 84.03 80.04 Cash Conversion Cycle 9.46 1.45 11.40 -27.27 -56.39 69.15 37.76 31.63 26.12 15.89 Total Debt/Equity 0.23 0.09 0.15 0.12 0.10 0.54 0.42 0.32 0.05 0.07 Interest Cover 9.98 12.24 8.07 36.27 86.40 37.81 41.70 160.20 102.16 173.43

Top Investors:

dsp midcap fund

life insurance corporation of india

kotak small cap fund

tata aia life insurance co ltd unit linked multi cap fund

investor education and protection fund (iepf)

Annual Reports:

News Update:

Alembic Pharmaceuticals gets USFDA’s final approval for Macitentan Tablets
19th Aug 2025, 12:30 PM

Macitentan Tablets, 10 mg, have an estimated market size of $1,180 million for twelve months ending June 2025 according to IQVIA
Read More
Alembic Pharmaceuticals gets USFDA’s final approval for Tretinoin Cream
16th Aug 2025, 10:09 AM

The company has a cumulative total of 224 ANDA approvals (202 final approvals and 22 tentative approvals)
Read More
Alembic Pharmaceuticals reports 15% rise in Q1 consolidated net profit
5th Aug 2025, 16:29 PM

The consolidated total income of the company increased by 9.81% at Rs 1717.22 crore for Q1FY26
Read More
Alembic Pharma - Quarterly Results
5th Aug 2025, 13:21 PM

Read More
Alembic Pharmaceuticals gets USFDA’s final approval for Carbamazepine Extended-Release Tablets
26th Jul 2025, 13:07 PM

Alembic has a cumulative total of 225 ANDA approvals (202 final approvals and 23 tentative approvals) from USFDA
Read More
Alembic Pharmaceuticals’ arm to acquire Utility Therapeutics
3rd Jul 2025, 09:39 AM

The objective behind the acquisition is to market the USFDA approved product and underdevelopment product owned by the Utility in USA
Read More
Alembic Pharmaceuticals gets final nod for Doxorubicin Hydrochloride Liposome Injection
30th Jun 2025, 10:11 AM

The company has a cumulative total of 224 ANDA approvals (201 final approvals and 23 tentative approvals) from USFDA
Read More
Alembic Pharmaceuticals gets EIR from USFDA for API-III facility at Karakhadi
18th Jun 2025, 14:51 PM

Earlier, the company had successfully completed the USFDA inspection for its API-III Facility located at Karakhadi
Read More
USFDA concludes inspection at Alembic Pharmaceuticals’ Gujarat API-I & II facility
2nd Jun 2025, 09:17 AM

The USFDA issued a Form 483 with four observations
Read More
Alembic Pharmaceuticals receives USFDA's final approval for Bosutinib Tablets
31st May 2025, 12:30 PM

The company has a cumulative total of 223 ANDA approvals (200 final approvals and 23 tentative approvals) from USFDA
Read More
Alembic Pharmaceuticals gets USFDA’s nod for Amlodipine and Atorvastatin Tablets
23rd May 2025, 15:30 PM

The company has a cumulative total of 223 ANDA approvals (199 final approvals and 24 tentative approvals) from USFDA
Read More

Alembic Pharmaceuticals Ltd.

Pharmaceuticals & Drugs - Global

BSE: 533573 | NSE: APLLTD

Stock Summary

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Earnings Forecasts:

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Consolidated Figures in Rs. Crores /

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Cash Flow

Consolidated Figures in Rs. Crores /

Financial Ratios

Consolidated /

Top Investors:

Annual Reports:

News Update:

Alembic Pharmaceuticals Ltd.

Pharmaceuticals & Drugs - Global

BSE: 533573 | NSE: APLLTD

Stock Summary

Shareholding Pattern

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Earnings Forecasts:

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Consolidated Figures in Rs. Crores /

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Cash Flow

Consolidated Figures in Rs. Crores /

Financial Ratios

Consolidated /

Top Investors:

Annual Reports:

News Update: